TY - JOUR T1 - c-Myc-driven Hepatocarcinogenesis JF - Anticancer Research JO - Anticancer Res SP - 4937 LP - 4946 DO - 10.21873/anticanres.15307 VL - 41 IS - 10 AU - HYUK MOON AU - HYUNJUNG PARK AU - SIMON WEONSANG RO Y1 - 2021/10/01 UR - http://ar.iiarjournals.org/content/41/10/4937.abstract N2 - Background/Aim: Dysregulation of the c-Myc gene is frequently found in human hepatocellular carcinoma (HCC), often accompanied by genetic and epigenetic alterations in other cancer-related genes. Here, we investigated the tumorigenic potential of c-Myc in diverse genetic environments in which the Ras, Wnt/β-catenin, Sonic hedgehog, or P53 pathways were either activated or inactivated. Materials and Methods: Hydrodynamic tail vein injection was employed to administer expression transposons and generate transgenic livers expressing c-Myc together with a constitutively active form of RAS (HRASG12V), β-catenin (β-cateninS33Y), Smo (SmoM2), or short hairpin RNA targeting P53 (shp53). Results: c-Myc was most tumorigenic when the RAS signaling pathway was activated, whereas no tumors were found in mice when either β-cateninS33Y or SmoM2 was co-expressed with c-Myc. Approximately 40% of mice had HCC when c-Myc was over-expressed under P53 inactivation. Furthermore, we investigated the effect of mutation in c-Myc on hepatocarcinogenesis. Conclusion: No significant differences in tumorigenic potential were found between wild type c-Myc and c-MycT58A, minimizing the role of the mutation in hepatocarcinogenesis. ER -